FINALLY! Indeed, in ways large and small, 2025 turned out to be a year in which patience was rewarded. The most obvious ...

Multiple PGA Tour winner and former U.S. Open champion Webb Simpson has confirmed he is back working with Paul Tesori.

Joe Greiner, who used to carry the sticks for Max Homa and two-time major champion Collin Morikawa, has confirmed his new ...

The Minnesota Vikings will start their third different quarterback of the season on Sunday against the Seattle Seahawks, as the team announced that undrafted rookie Max Brosmer will lead the offense ...

Minnesota Vikings quarterback J.J. McCarthy would be the first to tell you that growth isn’t a linear journey — but Week 11 against the Chicago Bears was a new low for the 22-year-old quarterback.

T.J. Watt has passed a familiar face on the NFL's career sack list. The Steelers' pass rusher now has more than his older brother JJ Watt, a current CBS Sports NFL color analyst who enjoyed a Hall of ...

The Minnesota Vikings’ playoff hopes took a big hit with Sunday’s 19-17 loss to the division rival Chicago Bears. The defeat dropped Minnesota to last place in the NFC North — three games behind the ...

Nov 17 (Reuters) - Johnson & Johnson (JNJ.N), opens new tab said on Monday it would buy privately held Halda Therapeutics for $3.05 billion in cash, aiming to expand its presence in treatments ...

Johnson & Johnson is paying $3.05 billion to acquire Halda Therapeutics, obtaining a novel cell death platform while strengthening its prostate cancer franchise built on Erleada. At the center of the ...

Minnesota Vikings starting quarterback J.J. McCarthy is in concussion protocol, head coach Kevin O'Connell announced Monday. Per O'Connell, McCarthy reported concussion symptoms on the flight back ...

Minnesota Vikings quarterback J.J. McCarthy missed five games due to an ankle injury that he suffered in Week 2. Following his return, the signal caller suffered another injury, leading to many ...

Johnson & Johnson’s attempt to develop a $5 billion-a-year Alzheimer’s disease drug has been rocked by a phase 2 flop. A scheduled data review found the anti-tau antibody posdinemab failed to ...